Recent reports have suggested a causative link between the use of interferon (INFα) treatment in chronic hepatitis C virus (HCV) infections and the development of myasthenia gravis.1 2 This presents something of a conundrum given that low dose INFα has been advocated as a treatment for myasthenia and seems to be well tolerated in those with established disease.3 Further confusion arises from the well established finding that untreated HCV infection itself leads to a markedly increased risk of developing various autoimmune conditions including rheumatoid arthritis, autoimmune thyroid disease, systemic lupus erythematosus, and polymyositis.4 A recent …